FujiFilm Cellular Dynamics, Inc.

CDI was founded in 2004 by Dr. James Thomson, a University of Wisconsin developmental biologist who in 1998 became the first scientist to isolate human embryonic stem cells, and in 2007 developed methods to reprogram adult cells into induced pluripotent stem cells (iPSCs). CDI commercialized the iPSC technology to manufacture consistent batches of human cells—initially cardiomyocytes, then neurons, hepatocytes, and others—for use in pharmaceutical research and toxicology screening.

Fujifilm Holdings acquired CDI in 2015 for $307 million, and the company now operates as a subsidiary within Fujifilm's Life Sciences division. This integration provides CDI with Fujifilm's global distribution network, manufacturing expertise, and balance-sheet support, while allowing the Madison operation to maintain a distinct brand identity and continue supplying cells to Fujifilm's pharmaceutical competitors on a non-exclusive basis.

No. CDI is a B2B supplier of human cell products and services to the pharmaceutical and biotechnology industries. It does not pursue internal therapeutic development. Its revenue comes from selling catalog iPSC-derived cells, custom disease-modeling services, and toxicity-screening platforms to drug developers. This model generates revenue independent of clinical-trial outcomes for the therapies tested using its cells.

CDI serves the preclinical drug-discovery and safety-pharmacology sectors. Its primary customers are pharmaceutical companies screening for cardiotoxicity, neurotoxicity, and hepatotoxicity. Secondary applications include academic researchers studying genetic disease mechanisms and CROs incorporating human iPSC-derived cells into their screening service offerings.

The iPSC-derived cells are manufactured at CDI's headquarters facility in Madison, Wisconsin, and distributed globally. Fujifilm's existing life-science logistics network, including subsidiaries in Japan and Europe, handles international distribution. The Madison facility's capacity was upgraded following the Fujifilm acquisition to support increasing demand from large pharmaceutical accounts.

CDI's differentiation comes from being the first to commercialize iPSC technology at scale, its manufacturing quality-control systems built over two decades, and its structural position as a neutral supplier that does not compete with its customers on therapeutic development. The Fujifilm balance sheet also provides stability that many independent biotech platform companies lack.

The FDA Modernization Act 2.0, signed into law in late 2022, removed the federal mandate that drug candidates must undergo animal testing before human trials. This regulatory shift opens the door for sponsors to use alternative methods—including iPSC-derived human cell assays—in preclinical safety submissions. As a major supplier of those assays, CDI is positioned to benefit from increased adoption of cell-based toxicology models.